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ABSTRACT
Objective: To evaluate the impact of a television
advertising campaign on the risk of oral ingestion of
a topical non-prescription gynaecological preparation
containing benzydamine hydrochloride.
Design: An interrupted time series design with data
routinely collected.
Setting: A National Poison Control Centre.
Participants: 215 cases of hazardous exposure to the
preparation under study occurred in Italy from January
2005 to December 2010.
Primary and secondary outcome
measures: Mean daily rate of cases of exposure by
gender in three different periods, that is,
pre-advertisement period, before the advertisement
was broadcast (from 1 January 2005 to 19 December
2009), advertisement period, when the advertisement
was repeatedly launched (from 20 December 2009 to
27 February 2010), post-advertisement period (from
28 February 2010 to 6 March 2010); observed/
expected ratios of cases, with expected cases based on
data from the pre-advertisement period, adjusted for
estimated variations in the number of users.
Comparison of the distribution of the main
characteristics of cases in the three different periods
by means of Pearson’s c
2 test or Fisher’s exact test.
Results: The adjusted observed/expected ratio of
cases in women was 7.48 (95% CI 5.76 to 9.56) in the
advertisement period and 2.97 (95% CI 2.24 to 3.85)
in the post-advertisement period. Regarding the
characteristics of cases, there was an increased
proportion of cases of exposure due to confusion
about the correct administration route in the
advertisement and post-advertisement periods
(81% and 55%, respectively, compared to 16% for the
pre-advertisement period.) and of individuals with
clinical effects (55%, 52% and 27%, respectively).
Conclusions: In Italy, an advertisement for
a non-prescription medicine seems to have confused
consumers regarding the administration route. This
effect was observed even after the advertisement
had stopped being broadcast. These results highlight
the need for the monitoring of medication errors
and adverse effects before, during and after
advertising.
INTRODUCTION
Benzydamine hydrochloride (BHC) (CAS
no. 132-69-4) is a local anti-inﬂammatory and
analgesic active ingredient ﬁrst synthesised
by the Angelini research laboratories in the
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ARTICLE SUMMARY
Article focus
- The study is focused on documenting the impact
of television advertising on the safe use of
a benzydamine hydrochloride-containing gynae-
cological preparation in Italy.
Key messages
- Advertising can affect the safe use of medicine.
Select outcomes, such as medication errors,
should be carefully monitored before, during and
after advertising campaigns. To this end, poison
control centres can be extremely useful.
Strengths and limitations of this study
- The study is based on routinely collected and
readily available data (ie, reports and telephone
calls made to a National Poison Control Centre),
which allowed for the comparison of the main
characteristics of cases of dangerous exposure
to a medicine and for the evaluation of the
association between the occurrence of cases and
a television advertising campaign. The main
potential limitation is that the data were provided
on a voluntary basis to the poison control centre,
so that they may not be representative of all
cases occurring in the general population.
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Open Access Researchmid-1960s. Since then, topical preparations containing
BHC have been marketed worldwide for the symptom-
atic treatment of oropharyngeal and gynaecological
conditions.
1 These preparations are sold as concentrated
or ready-to-use solutions or as a powder to be dissolved
in water. Topical preparations of BHC are usually well
tolerated, with infrequent side effects.
2 Absorption
through the skin and mucosa is low, whereas experi-
mental data indicate that BHC is rapidly absorbed in the
gastrointestinal tract.
34A limited number of reports on
acute oral exposure in humans have shown that BHC
overdose can cause nausea, vomiting, visual hallucina-
tions, oesophageal irritation, agitation and
somnolence.
5e8 These effects have resulted mainly from
the ingestion of gynaecological preparations because of
confusion about the correct administration route and
the preparations being mistaken for oral medicines.
8 A
few cases of injuries due to intentional ingestion for
recreational use have also been reported.
79
In Italy, from 1977 to 2009, BHC-containing gynaeco-
logical preparations manufactured by Angelini were
classiﬁed as pharmacy-supervised drugs (sold under the
supervision of a pharmacy), a category of non-prescrip-
tion drugs for which advertising to the public is
prohibited. In April 2009, these preparations were
reclassiﬁed as over-the-counter (OTC) drugs with the
following therapeutic indications: vulvovaginitis of any
origin or nature, characterised by small vaginal
discharge, itching, irritation, burning and vulvar pain;
and personal hygiene during puerperium. The label on
the package was changed from ‘vaginal solution’ to
‘cutaneous solution for external genital organs’.
10 Given
the drug’s new status, advertising to the public was
allowed, and the manufacturer launched an intensive
television advertising campaign between 20 December
2009 and 2 January 2010, followed by a second campaign
between 17 and 23 January 2010. The advertisement
focused on solidarity among women and on their ability
to solve their ‘intimate problems’ by using the advertised
preparation. At the end of the advertisement, an allusion
was made to the mode of use, with a woman’s silhouette
with concentric circles on the abdomen.
During the ﬁrst television campaign, the National
Poison Control Centre in Milan (PCCM) observed an
unexpectedly increased number of requests for assis-
tance for cases of unintentional oral ingestion (ie, from
approximately one case per month to two cases per day).
Based on these ﬁndings, the Italian Ministry of Health
required that the advertisement be revised to clarify that
the product was for topical use. The advertisement was
rebroadcast between 21 and 27 February 2010, with
a written statement at the end of the advertisement
stating that the preparation was for topical use only
and a woman’s silhouette with concentric circles on the
pubis area. Afterwards, the advertisement was
voluntarily stopped by the manufacturer. The objective
of the present study was to document how unintentional
oral exposure to BHC-containing gynaecological
preparations was inadvertently promoted by television
advertising in Italy.
MATERIALS AND METHODS
Each year, the PCCM receives approximately 42000
reports of human exposure to different types of
substances,
11 accounting for more than 60% of all cases
referred to Italian PCCs.
12 The PCCM mainly provides
consultation to hospitals (60% of cases) and to the
general public (30% of cases) throughout Italy. Assis-
tance for diagnosing and treating poisonings is provided
by medical toxicologists, mainly over the phone. For
each case, the toxicologist collects the following data in
real time using a standard form: demographic charac-
teristics, exposure characteristics (eg, substance/
commercial product, route of exposure, reason for
exposure, dose and latency between exposure and
onset of clinical effects), signs and symptoms, therapy
and outcome. About 45% of the human exposures
managed by the PCCM are medicine-related; of these,
about 17% are victims of the inappropriate use of
medication.
13
For the present study, the PCCM database was
searched from 1 January 2005 to 31 December 2010
to identify all cases of inappropriate exposure to the
BHC-containing gynaecological preparation, which is
available in diverse forms (ie, concentrated solution,
ready-to-use solution and powder). A clinical toxicologist
(FD) reviewed the available information for data
consistency and to grade the severity of outcome
according to the Poisoning Severity Score (ie, none,n o
signs/symptoms; minor, mild, transient and spontane-
ously resolving signs/symptoms; moderate, pronounced
or prolonged signs/symptoms; severe, life-threatening
signs/symptoms or resulting in signiﬁcant residual
disability or disﬁgurement; fatal, death as a result of
exposure or of direct complications of the exposure
effects).
14 For the purposes of the present analysis, the
identiﬁed cases were classiﬁed into three groups based
on exposure period: (1) the pre-advertisement period (ie,
from 1 January 2005 to 19 December 2009), before the
advertisement was broadcast; (2) the advertisement period
(ie, from 20 December 2009 to 27 February 2010), when
the advertisement was repeatedly launched, plus the
week following the last day of broadcast (ie, from
28 February 2010 to 6 March 2010), assuming that the
advertisement still had an effect and (3) the post-adver-
tisement period (ie, from 7 March 2010 to 31 December
2010).
The mean number of packages sold per day during
these periods was estimated based on the information
provided by the manufacturer on the number of pack-
ages sold per month from November 2009 to October
2010 We assumed that the sales during the pre-advertise-
ment period remained constant; we thus decided to
calculate the mean number of packages sold per day
based on sales in November 2009 (n¼83745, corre-
sponding to 2791 packages/day). Since the ﬁrst 20 days
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period, the quantity assumed to be sold in these 20 days
(55820 packages) was based on the estimated daily sales
in November 2009. This quantity was subtracted from
the total number of packages sold in December
(n¼173724). The remaining quantity (117904 pack-
ages) was used to estimate the mean number of pack-
ages/day sold in the period 20e31 December
(n¼10718) under the assumption that the observed
increase was completely driven by advertising. During
the entire advertisement period, an estimated mean of
8381 packages/day were sold, whereas in the post-adver-
tisement period, a mean of 4764 packages/day were esti-
mated to be sold. The ratio of advertisement period sales
to pre-advertisement sales and the ratio of post-advertisement
sales to pre-advertisement sales were calculated as an indi-
cator of the increased number of users (ie, the popula-
tion at risk of exposure). These ratios corresponded to
a 3.0-fold mean increase in the advertisement period
(range, by calendar month: 2.1e3.8) and a 1.7-fold
mean increase in the post-advertisement period (range,
1.2e2.1).
The mean daily rate (ie, the mean number of cases of
exposure/day) by gender and period was calculated, as
were the 95% CIs, assuming a Poisson’s process. In the
pre-advertisement period, the mean daily rate for both men
and women was assumed to be constant over time and
used to estimate the expected number of cases in the
advertisement and post-advertisement periods. These
expected values were adjusted by the estimated increases
in the population at risk of exposure in the two periods.
The ratio of observed to adjusted expected cases (O/E)
was used as a measure of the association between inap-
propriate exposure and television advertising. The 95%
CIs of the O/E ratio were derived assuming a Poisson’s
process for the observed cases.
15 The main characteris-
tics of cases in the three periods were compared using
Pearson’s c
2 test or Fisher’s exact test.
RESULTS
A total of 215 cases of oral exposure to the advertised
gynaecological preparations were identiﬁed. Of these,
187 were women and 28 were men. All cases were
unintentionally exposed through oral ingestion, with the
exception of one man who intentionally ingested the
preparation.
The mean number of cases/day observed by month in
the three different periods is shown in ﬁgure 1; the
mean number of packages sold per day is also shown. In
the pre-advertisement period, there were 15e20 cases/year
and 0e4 cases/month. The mean number of cases/day
by month ranged from 0.00 to 0.15. In the advertisement
period, 1.85 cases/day were observed during the last
10 days of December, which were completely covered by
the ﬁrst advertising campaign. In January, 1.00 cases/day
were observed; the beginning of this month was covered
by the ﬁrst advertising campaign, which was broadcast
until 2 January, and, subsequently, from 17 to 23 January
by the second advertising campaign. In February, 0.48
cases/day were observed; the third advertising campaign
was broadcast from 23 to 27 February. The estimated
number of packages sold per day varied from 10718 in
the last 10 days of December, to 6142 in January, and to
5788 in February. During the post-advertisement period
(ie, from 7 March 2010 to 31 December 2010), the mean
number of cases/day ranged from 0.10 to 0.35. The
estimated number of packages sold per day ranged from
6000 to 3373.
The distribution of cases by gender and period and
the corresponding daily rates are shown in table 1. The
Figure 1 Distribution by month
of the mean number of cases/day
exposed to benzydamine
hydrochloride-containing
gynaecological preparation
reported to the National Poison
Control Centre in Milan
2005e2010 and the mean number
of packages/day sold in Italy
between November 2009 and
October 2010.
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Oral ingestion of benzydamine hydrochloride-containing gynaecological preparationobserved/expected ratios, adjusted by the estimated
increase in the population at risk of exposure (ie, 3.0-
and 1.7-fold increase in the advertisement and post-adver-
tisement period, respectively), are also shown. In the
pre-advertisement period, 67 cases occurred in women,
accounting for 0.04 cases/day (95% CI 0.03 to 0.05) and
20 cases occurred in men (0.01 cases/day, 95% CI 0.01 to
0.02). In the advertisement period, in women, there were
64 observed cases and 8.55 expected cases (O/E 7.48,
95% CI 5.76 to 9.56), whereas in men, the observed cases
were close to the expected ones (3 vs 2.54, O/E 1.18,
95% CI 0.24 to 3.45). In the post-advertisement period, in
women, there were 56 observed cases and 18.87
expected cases (O/E 2.97, 95% CI 2.24 to 3.85). In men,
there were ﬁve observed cases and 5.63 expected cases
(O/E 0.89, 95% CI 0.29 to 2.07).
The main characteristics of female cases by period of
exposure are reported in table 2. In the advertisement and
post-advertisement periods, the percentage of women
(95% and 92%, respectively) was signiﬁcantly higher
than that in the pre-advertisement period (76%, p¼0.001
and 0.025, respectively). The percentage of individuals
who were hospitalised in the advertisement period (52%)
was slightly higher, though not signiﬁcantly, than that in
the pre-advertisement (42%) and post-advertisement (43%)
periods. When comparing cases in the pre-advertisement
and advertisement periods, signiﬁcantly different distri-
butions were found for age class (p¼0.003), reason for
exposure (p<0.001) and medical outcome (p¼0.002).
In particular, the advertisement period, compared to the
pre-advertisement period, was characterised by a predomi-
nance of cases aged 20e49 years (77% vs 46%), medi-
cation error due to misunderstanding of the correct
mode of use (81% vs 16%) and individuals suffering
recognised BHC-related effects (55% vs 27%). In the
post-advertisement period, the distribution of cases by age
was comparable to that reported in the pre-advertisement
period, whereas signiﬁcant differences were found for
the distribution of cases by reason of exposure
(p<0.001) and medical outcomes (p¼0.005).
Altogether, 82 women suffered recognised BHC-
related effects. The severity of medical outcomes was
minor in 70 women (85%) and moderate in 12 (13%).
No severe or fatal effects were observed. The signs and
symptoms most frequently associated with BHC inges-
tion included vertigo (n¼26), pyrosis (n¼25), oropha-
ryngeal irritation (n¼19), vomiting (n¼19), nausea
(n¼14), hallucinations (n¼7), pharyngeal pain (n¼6)
and headache (n¼6) (table 2).
With reference to men exposed in the pre-advertisement
period (n¼20), 50% mistook a BHC solution for
drinking water or other beverage, whereas for the
remaining 50%, the exposure was due to confusion with
other medicine. Similarly, in the advertisement period, two
cases reported having mistook a BHC solution for
a beverage and one for another medicine. Among the
ﬁve cases detected in the post-advertisement period, in one
case the exposure was due to intentional abuse; one case
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Oral ingestion of benzydamine hydrochloride-containing gynaecological preparationeach mistook the solution for a beverage or another
medicine. Altogether, six patients were symptomatic and
suffered oropharyngeal irritation (n¼3) and vomiting
(n¼3).
COMMENTS
In the European Community, advertising to the public is
only allowed for medicinal products that are classiﬁed as
‘not subject to medical prescription’,
16 commonly
referred to as ‘OTC’. This classiﬁcation should be based
on an evaluation of the balance between the potential
beneﬁts of the products being readily available for
self-treatment and the potential harm resulting from
unsupervised or inappropriate use. Thus, the safety of
OTC medicines needs to be continuously monitored, to
identify unforeseen problems and implement suitable
interventions to minimise the potential for harm.
17e19
Advertising to the public is a source of information
that tends to emphasise the beneﬁcial effects of the
advertised product,
20 which could inadvertently
contribute to unnecessary or inappropriate use.
However, the impact of advertising to the public on the
safe use of non-prescription medicines has only been
studied to a limited extent.
21 22
Table 2 Main characteristics of female cases of ingestion of a benzydamine hydrochloride-containing gynaecological
preparation reported to the National Poison Control Centre in Milan in 2005e2010
Period
Pre-advertisement
(67 cases)
Advertisement
(64 cases)
Post-advertisement
(56 cases)
n (%) n (%) p* n (%) p*
All cases 88 67 61
Women 67 (76.1) 64 (95.5) 0.001 56 (92.0) 0.025
Site of call for assistance 0.294 0.932
Hospital 28 (41.8) 33 (51.6) 24 (42.9)
Private residence 24 (35.8) 15 (23.4) 21 (37.5)
Other 15 (22.4) 16 (25.0) 11 (19.6)
Age (years) 0.003 0.777
<5 6 (8.9) 0 (0.0) 3 (5.4)
5e19 14 (20.9) 4 (6.2) 9 (16.1)
20e34 21 (31.3) 33 (51.6) 20 (35.7)
35e49 10 (14.9) 16 (25.0) 12 (21.4)
50 + 14 (20.9) 10 (15.6) 9 (16.1)
Unknown 2 (3.0) 1 (1.6) 3 (5.4)
Reason for exposure <0.001 <0.001
Unintentionaldgeneraly 21 (31.3) 4 (6.2) 8 (14.3)
Unintentionaldmedication error
Medicine exchange 35 (52.2) 8 (12.5) 17 (30.4)
Incorrect route 11 (16.4) 52 (81.2) 31 (55.4)
Preparation
500 mg granular form 65 (97.0) 60 (93.8) 47 (83.9)
Others 1 (2.3) 3 (4.7) 9 (16.1)
Unknown 1 (1.1) 1 (1.6) 0 (0.0)
Medical outcomes 0.002 0.005
None 49 (73.1) 29 (43.7) 27 (48.2)
At least one sign or symptom 18 (26.9) 35 (54.6) 29 (51.8)
Minor 17 (25.4) 31 (48.4) 22 (39.3)
Moderate 1 (1.5) 4 (6.2) 7 (12.5)
Clinical effects
Vertigo 6 (8.9) 12 (18.7) 8 (14.3)
Pyrosis 3 (4.5) 9 (14.1) 13 (23.2)
Oropharyngeal irritation 7 (10.4) 11 (17.2) 1 (1.8)
Vomiting 5 (7.5) 5 (7.8) 9 (16.1)
Nausea 3 (4.5) 7 (10.9) 4 (7.1)
Hallucinations 1 (1.5) 3 (4.7) 3 (5.4)
Pharyngeal pain 2 (3.0) 4 (6.2) 0 (0.0)
Headache 0 (0.0) 4 (6.2) 2 (3.6)
Other 6 (8.9) 9 (13.4) 12 (21.4)
*Comparison with the pre-advertisement period using Pearsons’ c
2 test or Fisher’s exact test.
yIncluding cases who mistook BHC solution for drinking water or other beverages.
BHC, benzydamine hydrochloride.
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Oral ingestion of benzydamine hydrochloride-containing gynaecological preparationSome studies have shown that self-medication of
vaginal conditions with OTC antifungal preparations is
associated with unnecessary use and a delay in proper
diagnosis and treatment.
23 24 With speciﬁc regard to
BHC-containing gynaecological preparations, a study
in Spain has shown a high frequency of medication
error due to misunderstandings about the correct
administration route.
8
In Italy, until April 2009, BHC-containing gynaeco-
logical preparations had been classiﬁed in a category of
medicines that can be obtained without a prescription
yet for which advertising to the public is not allowed.
The re-classiﬁcation as ‘OTC’ was not associated per se
with an increase in cases of exposure (ﬁgure 1) or with
changes in the case distribution by gender or other
characteristics. Instead, the daily rate of cases of expo-
sure reported to the National PCCM increased abruptly
in association with television advertising, and this
increase can be explained only in part by the increased
number of users. In particular, during the ﬁrst adver-
tising campaign (ie, 20 December 2009e2 January
2010), there was a 17.5-fold increase in the daily rate of
cases of oral exposure compared to the pre-advertisement
period, but only a 3.8-fold increase in the number of
users; when adjusting for the number of users, there was
still a 9.5-fold increase in the daily rate of cases. The
analysis of the observed/expected ratio, which was
performed taking into account a mean 3.0-fold increase
in the number of users during the advertisement period,
showed a statistically signiﬁcant 7.5-fold increase in the
risk of exposure in association with advertising. In the
post-advertisement-period, when the estimated number of
users was on average 1.7-fold higher than that in the
pre-advertisement period, the risk of exposure was
approximately three times higher than that in the pre-
advertisement period, suggesting that the advertisement
had a long-lasting effect.
The comparison of the main characteristics of female
cases in the different periods revealed an abrupt increase
in association with advertising not only for the occur-
rence of cases but also for the percentage of cases due to
misunderstandings about the administration route,
which was the main reason for exposure during the
advertisement period. In the last 11 days of December,
which fell within the period of the ﬁrst advertising
campaign, 100% of the female cases were exposed
because of confusion over the administration route; this
percentage was 81% when considering the entire adver-
tisement period, whereas in the 5-year pre-advertisement
period, it was only 16% (table 2). The television adver-
tisement, which was discontinuously broadcast,
emphasised the ability of women to achieve a quick
remission of their ‘intimate problems’ by simply going to
a pharmacy and buying the product. During the ﬁrst two
campaigns, the advertisement did not contain any direct
indication of the mode of use. In the third campaign, it
included a written statement that the preparation was for
topical-only use. However, this attempt at clariﬁcation
did not seem to have any effect, given that nine of the 11
cases observed during the last advertising campaign were
exposed because of incorrect administration route,
though there are too few cases to make a deﬁnitive
conclusion. The percentage of women who misunder-
stood the correct mode of use decreased during the post-
advertisement period, yet it remained higher than that in
the pre-advertisement period, indicating that the
misleading effect of the advertisement was long lasting.
A strength of this study was that it was based on
routinely collected and readily available data and that
during the study period the means of collecting data did
not change. However, a potential limitation of the study
is that there may have been a selection bias in the
population, which consisted of reports provided on
a voluntary basis to the National PCCM. Nonetheless, the
observed increase in the risk of exposure due to an
incorrect administration route can hardly be explained
by selection bias and can be reasonably considered to be
indicative of an increased risk of this type of incident
among users in the general population.
The reported ﬁndings document how advertising to
the public can negatively affect the correct use of an
OTC medication, highlighting the need for monitoring
select outcomes, such as medication errors and adverse
effects, before, during and after advertising campaigns.
Data routinely collected by PCCs, although referring to
a select subset of cases of dangerous exposure and
poisoning, can be useful in advertising surveillance and
provide valuable information for regulatory agencies.
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